NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

Phase 1

Terminated

Conditions: Cervical Cancer
Cervical Intraepithelial Neoplasia Grade 2
Cervical Intraepithelial Neoplasia Grade 3

Interventions: Drug: motexafin lutetium
Procedure: loop electrosurgical excision procedure
Drug: photodynamic therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00005808

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Lymphoepithelioma of the Oropharynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
Recurrent Mucoepidermoid Carcinoma of the Oral Cavity

Interventions: Drug: hydroxyurea
Drug: fluorouracil
Biological: bevacizumab
Radiation: radiation therapy
Biological: filgrastim
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00023959

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Drug: carboplatin
Drug: etoposide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00027898

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

Decitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Male Breast Cancer
Recurrent Bladder Cancer
Recurrent Breast Cancer
Recurrent Melanoma
Stage III Melanoma
Stage IV Bladder Cancer
Stage IV Breast Cancer
Stage IV Melanoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: decitabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00030615

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Acute Undifferentiated Leukemia
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blastic Phase Chronic Myelogenous Leukemia
Childhood Myelodysplastic Syndromes
Chronic Eosinophilic Leukemia

Interventions: Drug: imatinib mesylate
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00025415

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Brachytherapy in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00045474

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 6 locations

Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00032097

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Carmustine in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004028

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 6 locations

Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Duct Cell Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer

Interventions: Drug: bortezomib
Drug: gemcitabine hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT00052689

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

Phase 1

Completed

Conditions: Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: cytarabine
Drug: mitoxantrone hydrochloride
Drug: alvocidib
Other: pharmacological study
Other: laboratory procedure

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT00016016

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Home Terms & Conditions Privacy Policy